• Veraxa Biotech entered a strategic research collaboration with Secarna to develop antibody oligonucleotide conjugates for autoimmune, chronic immune diseases.
• Early in vitro work produced an AOC candidate with higher potency than the equivalent unconjugated oligonucleotide.
• Partners are discussing next steps, aiming to advance targeted delivery to improve bioavailability, reduce off-target effects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240700OMX_____CNEWS_EN_GNW1001258920_en) on August 24, 2026, and is solely responsible for the information contained therein.